Financings
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING

LSL · Price
Executive Summary
- LSL Pharma Group completed the acquisition of Juno OTC Inc. for a total purchase price of $5 million, consisting of cash, shares, and a deferred cash balance.
- Concurrently, the company closed an upsized $12 million private placement, including a $2 million tranche of non-brokered convertible debentures, bringing total gross proceeds to $12 million.
- The acquisition involves an arm's length transaction subject to TSXV approval, with operational control of Juno OTC remaining with the Seller until January 1, 2026.
Key Details
- Acquisition Structure:
- Target: Juno OTC Inc. (Toronto-based subsidiary of Juno Pharmaceuticals LP).
- Total Purchase Price: $5,000,000.
- Payment Terms:
- $2,500,000 in cash paid on December 23, 2025.
- 5,509,642 Class "A" common shares issued on the closing date.
- $500,000 in cash payable on January 1, 2027 (subject to working capital adjustments).
- Operational Control: Seller retains operational control and financial liability through December 31, 2025; Corporation assumes full control effective January 1, 2026.
- Regulatory Status: Qualifies as an "Expedited Acquisition" under TSXV Policy 5.3; subject to final TSXV approval. Securities issued are subject to a 4-month and 1-day statutory hold period.
- Financing Details (Non-Brokered Private Placement):
- Instrument: Unsecured convertible debentures.
- Quantity: 2,000 Debentures.
- Price: $1,000 per Debenture.
- Gross Proceeds: $2,000,000.
- Interest: 10.0% per annum, payable semi-annually in arrears.
- Maturity: December 31, 2029.
- Conversion: Convertible into Common Shares at a price of $0.45 per share.
- Seller Subscription: Juno Pharmaceuticals LP subscribed for $1,500,000 of the debentures.
- Total Capital Raised:
- Previous Brokered Offering: $10,000,000.
- Current Non-Brokered Offering: $2,000,000.
- Aggregate Gross Proceeds: $12,000,000.
- Target Business Profile: Juno OTC is a supplier in the Canadian private label consumer healthcare OTC market, holding required Health Canada licenses for importing and distribution.
Notable Quotes
- No direct quotes from the CEO/President were included in the provided text.
More from LSL Pharma Group Inc.
May 28, 2026 · 07:00